Nurix Therapeutics
Stock Forecast, Prediction & Price Target
Nurix Therapeutics (NRIX) stock Price Target by analysts
$34.57
Potential upside: 249.55%
Nurix Therapeutics price prediction
What is Nurix Therapeutics stock analysts` prediction?
Nurix Therapeutics stock forecast: Based on 7 Wall Street analysts` predicted price targets for Nurix Therapeutics in the last 3 months, the avarage price target is $34.57, with a high forecast of $NaN. The average price target represents a 249.55% change from the last price of $9.89.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Nurix Therapeutics stock Price Target by analysts
Full breakdown of analysts given Nurix Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Etzer Darout BMO Capital | 0% 0/1 | 9 months ago | $35 253.89% upside | $20.06 | StreetInsider | Previous targets (0) |
David Dai UBS | 0% 0/1 | 11 months ago | $35 253.89% upside | $24.78 | StreetInsider | Previous targets (0) |
Robert Burns H.C. Wainwright | 0% 0/2 | 11 months ago | $30 203.33% upside | $25.19 | StreetInsider | Previous targets (1) |
Matthew Biegler Oppenheimer | 0% 0/2 | 11 months ago | $35 253.89% upside | $24.87 | TheFly | Previous targets (1) |
Derek Archila Wells Fargo | 0% 0/2 | 11 months ago | $32 223.55% upside | $25.16 | StreetInsider | Previous targets (1) |
Stephen Willey Stifel Nicolaus | 0% 0/1 | 11 months ago | $34 243.78% upside | $24.98 | StreetInsider | Previous targets (0) |
Roger Song Jefferies | 0% 0/1 | 11 months ago | $41 314.56% upside | $23.04 | Benzinga | Previous targets (0) |
Brian Skorney Robert W. Baird | 0% 0/1 | about 1 year ago | $26 162.89% upside | $24.44 | TheFly | Previous targets (0) |
Matthew Biegler Oppenheimer | 0% 0/2 | about 1 year ago | $27 173.00% upside | $21.92 | StreetInsider | Previous targets (1) |
Gregory Renza RBC Capital | 0% 0/2 | about 1 year ago | $26 162.89% upside | $20.7 | StreetInsider | Previous targets (1) |
Robert Burns H.C. Wainwright | 0% 0/2 | about 1 year ago | $26 162.89% upside | $18.44 | StreetInsider | Previous targets (1) |
Tyler Van Buren Piper Sandler | 0% 0/1 | over 1 year ago | $35 253.89% upside | $15.95 | StreetInsider | Previous targets (0) |
Gregory Renza RBC Capital | 0% 0/2 | over 1 year ago | $23 132.55% upside | $15.69 | StreetInsider | Previous targets (1) |
Joel Beatty Robert W. Baird | 0% 0/1 | over 1 year ago | $25 152.78% upside | $15.69 | StreetInsider | Previous targets (0) |
Unknown Leerink Partners | N/A | over 2 years ago | $28 183.11% upside | $12.26 | Benzinga | N/A |
Derek Archila Wells Fargo | 0% 0/2 | over 3 years ago | $25 152.78% upside | $10.09 | Pulse 2.0 | Previous targets (1) |
Nurix Therapeutics Financial Estimates
Nurix Therapeutics Revenue Estimates
Nurix Therapeutics EBITDA Estimates
Nurix Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 11/30/2021 | 11/30/2022 | 11/30/2023 | 11/30/2025 | 11/30/2026 | 11/30/2027 | 11/30/2028 |
Revenue
% change YoY
| $29.75M N/A | $38.62M 29.83% | $76.98M 99.30% | Avg: $66.95M Low: $58.33M High: $84.84M avg. -13.03% | Avg: $75.71M Low: $57.43M High: $95.19M avg. 13.08% | Avg: $117.88M Low: $89.42M High: $148.22M avg. 55.70% | Avg: $267.42M Low: $202.86M High: $336.24M avg. 126.84% |
Net Income
% change YoY
| $-117.19M N/A | $-166.04M -41.68% | $-143.94M 13.30% | Avg: $-213.47M Low: $-191.31M High: $-140.19M avg. -48.30% | Avg: $-253.70M Low: $-224.40M High: $-80.96M avg. -18.84% | Avg: $-148.80M Low: $-198.58M High: $-102.10M avg. 41.34% | Avg: $-83.02M Low: $-110.80M High: $-56.97M avg. 44.20% |
EBITDA
% change YoY
| $-117.88M N/A | $-183.86M -55.97% | $-141.40M 23.09% | Avg: $-62.11M Low: $-78.71M High: $-54.11M avg. 56.07% | Avg: $-70.24M Low: $-88.32M High: $-53.28M avg. -13.08% | Avg: $-109.37M Low: $-137.52M High: $-82.97M avg. -55.70% | Avg: $-248.11M Low: $-311.96M High: $-188.21M avg. -126.84% |
EPS
% change YoY
| -$2.73 N/A | -$3.42 -25.27% | -$2.65 22.51% | Avg: -$3.05 Low: -$3.52 High: -$2.58 avg. -15.02% | Avg: -$3.34 Low: -$4.13 High: -$1.49 avg. -9.52% | Avg: -$2.74 Low: -$3.65 High: -$1.88 avg. 17.97% | Avg: -$1.53 Low: -$2.04 High: -$1.05 avg. 44.20% |
Operating Expenses
% change YoY
| $147.63M N/A | $222.49M 50.70% | $232.05M 4.29% | Avg: $49.45M Low: $43.08M High: $62.66M avg. -78.68% | Avg: $55.92M Low: $42.42M High: $70.31M avg. 13.08% | Avg: $87.07M Low: $66.05M High: $109.48M avg. 55.70% | Avg: $197.52M Low: $149.83M High: $248.35M avg. 126.84% |
FAQ
What is Nurix Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 4.60% in 2025-2028.
We have gathered data from 9 analysts. Their low estimate is -191.31M, average is -213.47M and high is -140.19M.
What is Nurix Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 45.65% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $58.33M, average is $66.95M and high is $84.84M.
What is Nurix Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 9.40% in 2025-2028.
We have gathered data from 9 analysts. Their low earnings per share estimate is -$3.52, average is -$3.05 and high is $-2.58.
What is the best performing analyst?
In the last twelve months 7 analysts have been covering Nurix Therapeutics stock. The most successful analyst is Etzer Darout.